JP2015158500A - アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 - Google Patents
アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 Download PDFInfo
- Publication number
- JP2015158500A JP2015158500A JP2015069056A JP2015069056A JP2015158500A JP 2015158500 A JP2015158500 A JP 2015158500A JP 2015069056 A JP2015069056 A JP 2015069056A JP 2015069056 A JP2015069056 A JP 2015069056A JP 2015158500 A JP2015158500 A JP 2015158500A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- soluble
- desmoglein
- peptide form
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 106
- 239000013543 active substance Substances 0.000 title claims abstract description 29
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 15
- 238000012216 screening Methods 0.000 title claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 title description 20
- 102000004169 proteins and genes Human genes 0.000 title description 19
- 102000011799 Desmoglein Human genes 0.000 title description 10
- 108050002238 Desmoglein Proteins 0.000 title description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 75
- 108010045579 Desmoglein 1 Proteins 0.000 claims abstract description 50
- 102000005708 Desmoglein 1 Human genes 0.000 claims abstract description 48
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 230000032683 aging Effects 0.000 claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 239000002537 cosmetic Substances 0.000 claims description 20
- 230000009759 skin aging Effects 0.000 claims description 16
- 238000012512 characterization method Methods 0.000 claims description 15
- 238000012286 ELISA Assay Methods 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000017854 proteolysis Effects 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 39
- 210000002615 epidermis Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 210000000434 stratum corneum Anatomy 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 12
- 210000002510 keratinocyte Anatomy 0.000 description 11
- 239000012634 fragment Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 102100038803 Somatotropin Human genes 0.000 description 4
- 108050007673 Somatotropin Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- KBHSAMYHDBBRKS-QTJGBDASSA-N 2-hydroxy-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]benzamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)C1=CC=CC=C1O KBHSAMYHDBBRKS-QTJGBDASSA-N 0.000 description 3
- 102100028288 Inactive serine/threonine-protein kinase VRK3 Human genes 0.000 description 3
- 101710123193 Inactive serine/threonine-protein kinase VRK3 Proteins 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000006375 Desmocollins Human genes 0.000 description 2
- 108010019063 Desmocollins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000761783 Homo sapiens Protein BRICK1 Proteins 0.000 description 2
- 101000915575 Homo sapiens Protein ZNRD2 Proteins 0.000 description 2
- 102100034868 Kallikrein-5 Human genes 0.000 description 2
- 101710176223 Kallikrein-5 Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100024841 Protein BRICK1 Human genes 0.000 description 2
- 102100028588 Protein ZNRD2 Human genes 0.000 description 2
- 102100027160 RuvB-like 1 Human genes 0.000 description 2
- 101710111834 RuvB-like 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NTMFVGXTEGZVRI-RXQQAGQTSA-N (2s,3s,4r)-2-aminooctadecane-1,3,4-triol;2-hydroxybenzoic acid Chemical class OC(=O)C1=CC=CC=C1O.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO NTMFVGXTEGZVRI-RXQQAGQTSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 102000005707 Desmoglein 2 Human genes 0.000 description 1
- 108010045583 Desmoglein 2 Proteins 0.000 description 1
- 102000007577 Desmoglein 3 Human genes 0.000 description 1
- 108010032035 Desmoglein 3 Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000004830 Super Glue Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- -1 cholesterol sulfates Chemical class 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
【解決手段】1以上の複合化した、または、複合化していない可溶性ペプチド形のデスモグレインIを、皮膚老化を防ぎ及び/又は処置するのに役立つ活性剤および/または処置、特にはアンチエイジング活性剤および/または処置、の有効性を評価する為のマーカーとして用いる方法。
【選択図】なし
Description
a)本発明に従う少なくとも1つの可溶形を放出することができる少なくとも1つの細胞タイプを、該可溶性ぺプチド形の放出にとって適当な条件下で、少なくとも1つの試験アンチエイジング活性剤との接触に付すること、
b)該可溶性ペプチド形の含有量を決定すること、及び
c)工程b)において決定された該含有量を、化学的又は生物学的試験化合物の不在下において決定された該可溶形の含有量と比較すること
からなる工程を少なくとも含む上記方法にも関する。
i.該個体を代表する少なくとも第1の皮膚表面試料を用意すること、
ii.該試料において、特にはELISAアッセイ技術により、特には本明細書以下の実施例1において記載されたとおりのELISAアッセイ技術により、本発明に従う少なくとも1つの可溶性ペプチド形を定量すること、
iii.該個体を代表する第2の皮膚表面試料に対して工程i.及びii.を繰り返すこと、及び
iv.工程ii.及びiii.の終わりで得られた結果を、特にはそれから該処置の少なくとも1つの効果に関する情報を推定する為に、比較すること、ここで該第1及び第2の皮膚表面試料は異なる処置段階に対応する、
からなる工程を少なくとも含む。
a)該上皮の表面試料における、本発明に従う少なくとも1つの可溶性ペプチド形の含有量を、特にはELISAアッセイ技術により、決定すること、及び
b)工程a)で決定された該含有量を参照値と比較すること
からなる工程を少なくとも含む。
a)本発明に従う少なくとも1つの可溶性ペプチド形を放出することができる少なくとも1つの細胞タイプを、該可溶性ペプチド形の放出にとって適当な条件下で、少なくとも1つの化学的若しくは生物学的試験化合物との接触に付すること、
b)該可溶性ペプチド形の含有量を決定すること、及び
c)工程b)において決定された該含有量を、化学的若しくは生物学的試験化合物の不在下において決定された該可溶形の含有量と比較すること
からなる工程を少なくとも含む上記方法に関する。
i.該個体を代表する少なくとも第1の皮膚表面試料を用意すること、
ii.該試料における、本発明における考慮下の少なくとも1つの可溶形を、特にはELISAアッセイ技術により、定量すること、
iii.該個体を代表する第2の皮膚表面試料について、工程i.及びii.を繰り返すこと、及び
iv.工程ii.及びiii.の終わりで得られた結果を、特にはそれから該処置の少なくとも1つの効果に関する情報を推定する為に、比較すること、ここで該第1及び第2の皮膚表面試料は異なる処置段階に対応する、
からなる工程を少なくとも含みうる。
Claims (12)
- 配列ID No.1の全部又は一部により表される核酸配列によりコードされるアミノ酸配列を有するポリペプチド又はその類似体に少なくとも部分的に由来する少なくとも1つの複合化した又は複合化していない可溶性ペプチド形を、皮膚老化を防ぎ及び/又は処置するのに役立つ活性剤をスクリーニングする為の手段として用いる方法。
- 該ペプチド形の存在又は含有量の増加の検出が、皮膚老化を防ぎ及び/又は処置するのに役立つ特性を有する活性剤を示す、請求項1に記載の方法。
- 該ペプチドが、配列ID No.2により表されるアミノ酸配列を有するポリペプチド又はその類似体のタンパク質分解に少なくとも部分的に由来する、請求項1又は2に記載の方法。
- 該ポリペプチドが、配列ID No.3、配列ID No.4、配列ID No.5、配列ID No.6、配列ID No.7、配列ID No.8、配列ID No.9、配列ID No.10、配列ID No.11、配列ID No.12、配列ID No.13、配列ID No.14、配列ID No.15、配列ID No.16、配列ID No.17、配列ID No.18、配列ID No.19、配列ID No.20、配列ID No.21、配列ID No.22、配列ID No.23、配列ID No.24、配列ID No.25、配列ID No.26、配列ID No.27、配列ID No.28、配列ID No.29、配列ID No.30、配列ID No.31、配列ID No.32、配列ID No.33、配列ID No.34、配列ID No.35、配列ID No.36、配列ID No.37、配列ID No.38、配列ID No.39、配列ID No.40、配列ID No.41、配列ID No.42、配列ID No.43、配列ID No.44、配列ID No.45、配列ID No.46、配列ID No.47、配列ID No.48、配列ID No.49、配列ID No.50、配列ID No.51、配列ID No.52、配列ID No.53、配列ID No.54、配列ID No.55、配列ID No.56、配列ID No.57、配列ID No.58、配列ID No.59、配列ID No.60、配列ID No.61、配列ID No.62、配列ID No.63、配列ID No.64、配列ID No.65、配列ID No.66、配列ID No.67、配列ID No.68、配列ID No.69、配列ID No.70、配列ID No.71、配列ID No.72、配列ID No.73、配列ID No.74、配列ID No.75、配列ID No.76、配列ID No.77、配列ID No.78、配列ID No.79、配列ID No.80、配列ID No.81、配列ID No.82、配列ID No.83、配列ID No.84及び配列ID No.85並びにそれらの混合物から選ばれる、請求項3に記載の方法。
- アンチエイジング活性剤をスクリーニングする方法であって、
a)請求項1〜4のいずれか1項に定義された少なくとも1つの可溶性ペプチド形を放出することができる少なくとも1つの細胞タイプを、該可溶性ペプチド形の放出にとって適当な条件下で、少なくとも1つの試験アンチエイジング活性剤との接触に付すること、
b)該可溶性ペプチド形の含有量を決定すること、及び
c)工程b)において決定された該含有量を、化学的又は生物学的試験化合物の不在下において決定された該可溶形の含有量と比較すること
からなる工程を少なくとも含む前記方法。 - 個体において、経時的老化と関連する皮膚老化の兆候を防ぎ及び/又は処置することが意図された化粧的又は治療的処置の有効性を特徴付ける為の方法であって、請求項1〜4のいずれか1項において定義された少なくとも1つの可溶性ペプチド形の定性的又は定量的特徴付けを少なくとも含む前記方法。
- 該可溶性ペプチド形の存在又は含有量の増加の検出又は特徴付けが、該活性剤の又は該処置の有効性を反映する、請求項5又は6に記載の方法。
- 個体における皮膚老化の兆候を防ぎ及び/又は処置することが意図された処置の有効性を特徴付けする為の非治療的方法であって、
i.該個体を代表する少なくとも第1の皮膚表面試料を用意すること、
ii.該試料において、特にはELISAアッセイ技術により、請求項1〜4のいずれか1項に記載の少なくとも1つの可溶性ペプチド形を定量すること、
iii.該個体を代表する第2の皮膚表面試料について工程i.及びii.を繰り返すこと、及び
iv.工程ii.及びiii.の終わりで得られた結果を比較すること、ここで該第1及び第2の皮膚表面試料は異なる処置段階に対応する、
からなる工程を少なくとも含む前記方法。 - 工程iv.における、該可溶性ペプチド形の存在の検出又は含有量の増加の検出が、該処置が有効であることを示す、請求項8に記載の方法。
- 該個体における、工程iv.の終わりで得られた情報に関して確立され又は選択された化粧的ケア組成物の施与により該処置を調節することからなる工程をさらに含む、請求項8又は9に記載の方法。
- 請求項1〜4のいずれか1項に定義された少なくとも1つの可溶性ペプチド形を、可溶形のデスモグレインIの放出を促進することができる活性な生物学的又は化学的化合物をスクリーニングする為の手段として用いる方法。
- 請求項1〜4のいずれか1項に定義された可溶性ペプチド形を、上皮の経時的皮膚老化の状態をin vitro又はex vivoで特徴付けする為の手段として用いる方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0950159 | 2009-01-13 | ||
FR0950159A FR2940976B1 (fr) | 2009-01-13 | 2009-01-13 | Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i |
US20207809P | 2009-01-27 | 2009-01-27 | |
US61/202,078 | 2009-01-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010004447A Division JP5820565B2 (ja) | 2009-01-13 | 2010-01-12 | アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015158500A true JP2015158500A (ja) | 2015-09-03 |
JP6284897B2 JP6284897B2 (ja) | 2018-02-28 |
Family
ID=41040658
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010004447A Expired - Fee Related JP5820565B2 (ja) | 2009-01-13 | 2010-01-12 | アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 |
JP2015069056A Expired - Fee Related JP6284897B2 (ja) | 2009-01-13 | 2015-03-30 | アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010004447A Expired - Fee Related JP5820565B2 (ja) | 2009-01-13 | 2010-01-12 | アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9316653B2 (ja) |
EP (1) | EP2209006B1 (ja) |
JP (2) | JP5820565B2 (ja) |
KR (1) | KR101431088B1 (ja) |
BR (1) | BRPI1002094A2 (ja) |
ES (1) | ES2564186T3 (ja) |
FR (1) | FR2940976B1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020501587A (ja) * | 2016-12-23 | 2020-01-23 | ロレアル | 皮膚の審美性の診断方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940977B1 (fr) | 2009-01-13 | 2016-11-18 | Oreal | Utilisation de formes complexes de la proteine de type calmodulin-like skin protein clsp |
CN102465182A (zh) * | 2010-10-29 | 2012-05-23 | 株式会社爱茉莉太平洋 | 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法 |
WO2014146051A1 (en) | 2013-03-15 | 2014-09-18 | Iris International, Inc. | Autofocus systems and methods for particle analysis in blood samples |
CN111982974B (zh) * | 2020-08-29 | 2023-06-02 | 西北民族大学 | 一种利用气味指纹图谱无创评价驴乳清蛋白肽抗衰老性能的方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11116493A (ja) * | 1997-10-08 | 1999-04-27 | Kao Corp | 細胞間接着抑制用経口投与剤 |
JP2001288113A (ja) * | 2000-04-05 | 2001-10-16 | Lion Corp | 皮膚外用剤組成物 |
JP2002012512A (ja) * | 1999-08-09 | 2002-01-15 | Shiseido Co Ltd | 外用組成物 |
US20030161853A1 (en) * | 2002-01-17 | 2003-08-28 | L'oreal | Methylglycinediacetic acid and deribatives thereof useful as exfoliating agents |
US20040142335A1 (en) * | 2001-01-03 | 2004-07-22 | Dirk Petersohn | Method for determining skin stress or skin ageing in vitro |
JP2004524010A (ja) * | 2000-11-30 | 2004-08-12 | モルキューラー スキンケア リミテッド | 疾患の診断および処置 |
JP2006006143A (ja) * | 2004-06-23 | 2006-01-12 | Hiroshima Univ | 伝染性膿痂疹の診断方法および診断キット、ならびにこれらに用いるポリペプチドおよび抗体 |
JP2007199053A (ja) * | 2005-12-28 | 2007-08-09 | Kose Corp | 角層蛋白質の検出方法並びにこれを利用する表皮ターンオーバーの評価方法及び肌状態評価方法 |
WO2008050811A1 (fr) * | 2006-10-26 | 2008-05-02 | Toyota Jidosha Kabushiki Kaisha | Dispositif d'aspiration de séparateur pour une pile à combustible |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US152599A (en) * | 1874-06-30 | Improvement in organ-couplers | ||
FR2667778B1 (fr) | 1990-10-16 | 1995-05-12 | Oreal | Cellule permettant de collecter sur la peau, par circulation de liquide, au moins un compose a doser. |
EP1075835A1 (en) | 1999-08-09 | 2001-02-14 | Shiseido Company Limited | Use of aminodiol derivatives in skin cosmeics |
JP2006008570A (ja) * | 2004-06-24 | 2006-01-12 | Club Cosmetics Co Ltd | 表皮剥離毒素阻害剤及びこれを用いた皮膚外用剤 |
FR2925312B1 (fr) * | 2007-12-19 | 2016-12-02 | Oreal | Utilisation cosmetique de proteines de type desmogleine i |
-
2009
- 2009-01-13 FR FR0950159A patent/FR2940976B1/fr not_active Expired - Fee Related
-
2010
- 2010-01-12 BR BRPI1002094-2A patent/BRPI1002094A2/pt not_active Application Discontinuation
- 2010-01-12 JP JP2010004447A patent/JP5820565B2/ja not_active Expired - Fee Related
- 2010-01-13 KR KR1020100003222A patent/KR101431088B1/ko active IP Right Grant
- 2010-01-13 EP EP10150607.9A patent/EP2209006B1/fr not_active Not-in-force
- 2010-01-13 ES ES10150607.9T patent/ES2564186T3/es active Active
- 2010-01-14 US US12/687,601 patent/US9316653B2/en not_active Expired - Fee Related
-
2015
- 2015-03-30 JP JP2015069056A patent/JP6284897B2/ja not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11116493A (ja) * | 1997-10-08 | 1999-04-27 | Kao Corp | 細胞間接着抑制用経口投与剤 |
JP2002012512A (ja) * | 1999-08-09 | 2002-01-15 | Shiseido Co Ltd | 外用組成物 |
JP2001288113A (ja) * | 2000-04-05 | 2001-10-16 | Lion Corp | 皮膚外用剤組成物 |
JP2004524010A (ja) * | 2000-11-30 | 2004-08-12 | モルキューラー スキンケア リミテッド | 疾患の診断および処置 |
US20040142335A1 (en) * | 2001-01-03 | 2004-07-22 | Dirk Petersohn | Method for determining skin stress or skin ageing in vitro |
US20030161853A1 (en) * | 2002-01-17 | 2003-08-28 | L'oreal | Methylglycinediacetic acid and deribatives thereof useful as exfoliating agents |
JP2006006143A (ja) * | 2004-06-23 | 2006-01-12 | Hiroshima Univ | 伝染性膿痂疹の診断方法および診断キット、ならびにこれらに用いるポリペプチドおよび抗体 |
JP2007199053A (ja) * | 2005-12-28 | 2007-08-09 | Kose Corp | 角層蛋白質の検出方法並びにこれを利用する表皮ターンオーバーの評価方法及び肌状態評価方法 |
WO2008050811A1 (fr) * | 2006-10-26 | 2008-05-02 | Toyota Jidosha Kabushiki Kaisha | Dispositif d'aspiration de séparateur pour une pile à combustible |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020501587A (ja) * | 2016-12-23 | 2020-01-23 | ロレアル | 皮膚の審美性の診断方法 |
JP2021166536A (ja) * | 2016-12-23 | 2021-10-21 | ロレアル | 皮膚の審美性の診断方法 |
Also Published As
Publication number | Publication date |
---|---|
FR2940976B1 (fr) | 2017-11-03 |
KR20100083741A (ko) | 2010-07-22 |
EP2209006A1 (fr) | 2010-07-21 |
US20100216165A1 (en) | 2010-08-26 |
CN101980022A (zh) | 2011-02-23 |
KR101431088B1 (ko) | 2014-10-07 |
JP6284897B2 (ja) | 2018-02-28 |
JP2010175538A (ja) | 2010-08-12 |
ES2564186T3 (es) | 2016-03-18 |
JP5820565B2 (ja) | 2015-11-24 |
BRPI1002094A2 (pt) | 2012-03-06 |
US9316653B2 (en) | 2016-04-19 |
FR2940976A1 (fr) | 2010-07-16 |
EP2209006B1 (fr) | 2015-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6284897B2 (ja) | アンチエイジング活性剤をスクリーニングするために可溶形のデスモグレインiタンパク質を用いる方法 | |
EP2453838B1 (en) | Cosmetic use of lacritin-type polypeptides | |
US8785397B2 (en) | Cosmetic use of apolipoprotein D type proteins | |
WO2009081368A2 (en) | Cosmetic use desmoglein i-type proteins | |
EP2224902A1 (en) | Cosmetic use of acid ceramidase type proteins | |
US20110038830A1 (en) | Cosmetic use of plakoglobin-type proteins | |
US10060931B2 (en) | Use of complex forms of calmodulin-like skin protein CLSP | |
EP2349319B1 (en) | Use of proteins of dj-1 type for characterizing skin dryness | |
US20110098230A1 (en) | Cosmetic use of annexin ii-type proteins for treating dryness of the skin | |
CN101980022B (zh) | 可溶性的桥粒芯糖蛋白i蛋白物质用于筛选抗衰老活性剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160324 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160822 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160926 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170622 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170922 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180131 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6284897 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |